Mind the gap: Precision medicine shortcomings in NSCLC
Hemonc Today | This year’s ASCO Annual Meeting included several major successes that should translate to new molecular targets in advanced non-small cell lung cancer, but recent real-world evidence should lead us to take a hard look in the mirror and realize we’re failing to deliver on the promise of the treatments we already have.Three other biomarkers — MET exon 14 mutation or high-level